دار الدواء
Dar Al Dawa

Non-Sedating

Loradad® (Loratadine)

DESCRIPTION:
Loradad (loratadine) is a long-acting and non-sedating tricyclic antihistamine with selective peripheral histamine H_1-receptor antagonistic activity.

PHARMACOLOGY :
Loratadine is rapidly absorbed and extensively metabolized in the liver to an active metabolite. Approximately 80% of the total dose administered can be found equally distributed between urine and feces in the form of metabolic products after 10 days. The mean elimination half-lives found in normal subjects were 8.4 hours for loratadine, and 28 hours for the major active metabolite.
About 97% of loratadine is bound to plasma protein.

INDICATIONS :
Loradad is indicated for the treatment of the following conditions:
- For the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis , such as sneezing, nasal discharge and itching as well as ocular itching and burning.
- For the management of idiopathic chronic urticaria, and other allergic dermatological disorders.

CONTRAINDICATIONS :
Loradad is contraindicated in patients who are hypersensitive to the drug, or to any of its ingredients.

SIDE EFFECTS :
The most common side effects reported were: headache, somnolence, fatigue and dry mouth. Rarely reported side effects were : abnormal hepatic function (including jaundice and hepatitis), alopecia, anaphylaxis, nausea and vomiting.

PRECAUTIONS:
Patients with liver impairment or renal insufficiency should be given a lower initial dose of 5 mg once daily or 10 mg every other day because they have a reduced clearance of loratadine.
Pregnancy : Since there are no adequate and well controlled studies in pregnant women, loratadine should be given only if the potential benefit justifies the potential risk to the fetus.
Nursing mothers: Loratadine is excreted in breast milk , caution should be exercised when loratadine is given to a nursing mother.

DOSAGE AND ADMINISTRATION:
- Adults and children 12 years of age and over: One 10 mg **Loradad** tablet once daily.
- Children (2 to 12) years of age:
  If body weight is 30 kg or more: 10 ml (two teaspoonful) **Loradad** syrup once daily.
  If body weight less than 30 kg: 5 ml (one teaspoonful) **Loradad** syrup once daily.

OVERDOSAGE:
Somnolence, tachycardia and headache have been reported with overdosage greater than 10 mg (from 40 - 180 mg).
In the event of overdosage, general symptomatic and supportive measures should be instituted promptly. The treatment consists of inducing emesis, except in patients with impaired consciousness, followed by administration of activated charcoal to absorb any remaining drug. If vomiting is unsuccessful or contraindicated, gastric lavage should be performed with normal saline . Loratadine is not eliminated by hemodialysis, and it is not known if loratadine is eliminated by peritoneal dialysis.

PRESENTATIONS:
Loradad tablets : Packs of 10, 20 tablets. Each tablet contains 10 mg Loratadine.
Loradad syrup : Bottles of 100 ml . Each 5 ml (teaspoonful) contain 5 mg Loratadine.

STORAGE CONDITIONS :
Loradad syrup : Store below 30°C, do not freeze.
Loradad tablets : Store in a dry place below 30°C.

THIS IS A MEDICAMENT
- Medicament is a product which affects your health , and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctors prescription, method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you .
- Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children

434085500 - 2 / 04
I - 2

Manufactured by Dar Al Dawa , Na'ur - Jordan